Optimizing Microdosing and Meditation (OMM)
Open-label, randomised feasibility trial (n=24) comparing psilocybin microdosing alone versus microdosing plus meditation in healthy adults; four supervised microdoses over two weeks.
Details
This randomised parallel-group feasibility study (n=24) assesses recruitment, retention, acceptability, safety, and preliminary signals of effect for psilocybin microdosing with and without a group-based meditation programme in healthy adults in Oregon.
Participants receive four supervised 2-hour microdosing sessions across two weeks; one arm also receives morning online meditation practice Monday–Friday and integrates meditation into sessions with group discussion and psychoeducation.
Outcomes include feasibility targets (recruit ≥20/24, ≥80% retention), safety (AEs/SAEs), participant satisfaction, Oura Ring biometric measures (sleep, HRV), PROMIS-29, FFMQ, PSQI, 11-ASC, and qualitative interviews.
Study procedures operate within Oregon's Psilocybin Services framework; investigators study facilitation of services rather than directly providing psilocybin, and participants are informed of legal considerations.